Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

抗血栓薬(Antithrombotic Drug)のグローバル市場(2014-2024)

◆タイトル:Antithrombotic Drugs: World Industry and Market Prospects 2014-2024
◆商品コード:Visiongain-4052625
◆調査・発行会社:visiongain
◆発行日:2014年2月
◆ページ数:175
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥278,845見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"抗血栓薬(Antithrombotic Drug)のグローバル市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場の促進要因、抑制要因、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Treating thrombosis – new analysis showing trends, R&D, and revenue forecasts
See the future of antithrombotic medicines. For those treatments you can get new sales predictions, also exploring research and development. Discover business potentials. And you assess results, trends, technologies, therapies, and opportunities.
Visiongain’s report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your influence.
Read on, then, to explore those drug sales and find what they could be worth in future.
Forecasts to 2024 and other analyses predict and explain the antithrombotics market
Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with recent results, growth rates, market shares, and discussions.
Also you find the potential of research and development. The study also gives 82 tables, 70 charts, and interviews with four authorities in that field.
There you assess the future for treatments to prevent blood clotting or to dissolve blood clots. The following sections explain what the new investigation gives.
Forecasting of that world market and its segments – what’s likely to happen?
What’re the secrets of that industry’s progress? Discover in our report overall world revenue to 2024 for antithrombotic medicines.
Also find individual revenue predictions to 2024 for eight therapeutic submarkets at world level:
• Antiplatelet agents
• Anticoagulants
• Fibrinolytic treatments.
And get forecasts for these anticoagulant drug classes:
• Heparins
• Direct thrombin inhibitors
• Direct factor Xa inhibitors
• Vitamin K antagonists
• Other therapeutics.
There you assess outlooks for sales expansion, hearing where you could profit. So investigate competition and rising sales. And see the lucrative possibilities there.
And you also find top products’ potentials.
Predictions of leading products’ sales
How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 15 brands. Assess products including these:
• Plavix
• Lovenox
• Pradaxa
• Xarelto
• Activase
• Effient.
There you find drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening, understanding challenges, trends, competition and opportunities.
That work also shows geographical revenue predictions.
National markets – what outlooks for revenues?
In developed and developing countries, many opportunities for producers and sellers of those medicines will occur from 2014 to 2024. See where and how.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations – Brazil, Russia, India, and China.
There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and needs.
Events affecting developers, producers, and sellers
The report also explains issues, forces, and events affecting the antithrombotics industry and market from 2014, including these:
• Opportunities for novel therapies, including biological drugs (biologics) and warfarin replacements
• Pulmonary embolism, stroke prevention and acute coronary syndrome (ACS) – needs for thrombotic disease management
• Generic competition and development of existing drugs
• Guidelines for approval of biosimilar low molecular weight heparins (LMWHs)
• Demand for antidotes to novel oral anticoagulants
• Vitamin K antagonist and direct factor Xa inhibitor R&D pipelines.
You find, then, what stimulates and restrains players in that sector, and affects its results.
Analysis of companies and potential for market growth – what revenues possible?
What happens next? From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from that applied haematology. Our study predicts that world market will reach $20.4bn in 2018.
You also see what organisations hold most potential. Examine companies, including these:
• Sanofi
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Bayer
• Johnson & Johnson.
And also these firms:
• The Medicines Company
• Genentech
• Otsuka
• Eli Lilly
• Sandoz.
You find 100 organisations mentioned. You also get four interviews with other authorities in that field, helping you stay ahead.
Ways Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 helps
In particular, our new investigation gives you this knowledge:
• Revenues there to 2024 at world level, for 8 submarkets, and 15 products – assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants – explore portfolios, results, strategies, R&D, and outlooks for success.
Information found nowhere else, helping your searches, analyses, and plans
Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.
So with our data you’re less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your planning, decisions, authority, and competing.
Our new report is for everyone analysing medications for thrombosis treatment and prevention. There you discover trends, discussions and sales predictions. Avoid missing out – please order now.

【レポートの目次】

1. Executive Summary
1.1 What This Report Covers
1.2 Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 Overview
1.3 Chapter Outlines
1.4 Research and Analysis Methods
1.5 Glossary of Terms in this Report
2. Blood Clotting: Mechanisms, Disorders and Current Treatments
2.1 Understanding Haemostasis and Coagulation
2.2 What is Thrombosis
2.3 Complications of Thrombosis
2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
2.4 Antithrombotic Drug Treatment
3. Antithrombotic Drugs: World Market 2014-2024
3.1 The World Antithrombotic Drug Market in 2012 and 2013
3.2 The World Antithrombotic Drug Market: An Overarching Revenue Forecast 2014-2024
3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
3.3.1 An Increasing Patient Population Drives Market Growth
3.3.2 Intense Competition from Generics Threatens to Restrain the Market
3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2018 and 2024
3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2024
3.6 Antiplatelet Drugs Were the Leading Therapeutic Class in 2012
3.7 Anticoagulant Drugs: Leading the Market from 2013 Onwards
3.7.1 Heparins: The Leading Anticoagulants of 2013, But Will This Continue?
3.7.2 Direct Thrombin Inhibitors Achieved High Growth in 2013
3.7.3 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
3.7.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market
4. Leading National Markets 2014-2024
4.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2012 and 2013?
4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2018 and 2024
4.3 Which National Markets Will Grow Fastest to 2024?
4.4 The US: Dominating the Antithrombotic Drug Market from 2014-2024
4.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
4.5.1 Germany Leads the EU5
4.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
4.5.3 UK: What Does the Introduction of a Value-Based Pricing System Mean for the Market?
4.5.4 Italy’s Healthcare System – Advantages Conducive to Pharma Business
4.5.5 Spain: Reductions in Government Healthcare Spending Will Restrict Growth
4.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2014-2024
4.7 The Chinese Antithrombotic Drug Market Will Capture Market Share
4.8 The Brazilian Antithrombotic Drug Market 2014-2024: Strong Growth as Universal Healthcare Coverage is Expanded
4.9 The Indian Antithrombotic Drug Market is Hindered by Limited Government Healthcare Spending
4.10 The Russian Antithrombotic Drug Market: Poor Healthcare Funding Will Prevent Expansive Growth
5. The Leading Products in the Market, 2014-2024
5.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition
5.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2018 and 2024
5.3 Which Medicines Will Achieve the Highest Rates of Growth to 2024?
5.4 Plavix Faces Competition From 14 Generic Competitors, So What Does the Future Hold?
5.4.1 Branded Competition for Plavix?
5.5 Lovenox: Biosimilar Competition in the EU is Expected
5.6 Pradaxa Was the Leading Novel Oral Anticoagulant in 2013, but the Race is Heating Up
5.7 Xarelto Leads the Direct Factor Xa Inhibitor Market
5.8 Activase Leads the Fibrinolytics Market, With Little Competition
5.9 Effient Competes with Brilinta as well as Generic Competition for Plavix
5.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
5.11 Angiomax is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
5.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
5.13 Aggrenox to Face Generic Competition Earlier Than Expected in the US
5.14 Sandoz’s Enoxaparin Sodium: Revenue Forecast 2014-2024
5.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
5.16 Arixtra: Aspen Has Acquired Worldwide Rights from GSK
5.17 Brilinta: Facing Investigation
5.18 Eliquis: Will Late Entry to the Market Affect Uptake?
6. The Antithrombotic Drug Development Pipeline 2014-2024
6.1 The R&D Pipeline for Antithrombotic Drugs: An Overview
6.2 The Antiplatelet Drug R&D Pipeline in 2014
6.2.1 FDA Advisory Committee Has Voted in Favour of Merck’s Vorapaxar
6.2.2 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
6.2.3 The Medicine Company’s Cangrelor Awaits Approval
6.3 The R&D Pipeline for Anticoagulants, 2014
6.3.1 Heparins: Little R&D Activity in 2014
6.3.1.1 Will Development of Momenta’s Adomiparin Continue?
6.3.1.2 The Discontinuation of Semuloparin
6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
6.3.4.1 Daiichi Sankyo’s Lixiani (edoxaban) Awaits Approval in the US and the EU
6.3.5 Portola Pharmaceuticals’ Betrixaban
6.3.6 Sanofi Has Discontinued Development of Otamixaban
6.4 The Fibrinolytics R&D Pipeline, 2014
6.4.1 Lundbeck’s Desmoteplase
6.4.2 Bharat Biotech and ThromboGenics’ THR-100
6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2013
6.5.1 Asahi Kasei Pharma America’s ART 123
6.5.2 Regado Biosciences is Developing an Anticoagulation System with an Antidote
6.5.3 Isis Pharmaceuticals’ ISIS-FXI Rx
7. Leading Companies in the Antithrombotic Drug Market
7.1 Leading Antithrombotic Drug Manufacturers in 2013
7.2 Sanofi Leads the Market, but is its Position Under Threat?
7.3 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013
7.4 Boehringer Ingelheim is Captures Market Share
7.5 Bayer Markets Two Antithrombotic Drugs
7.6 Johnson & Johnson Can Achieve Success With a Limited Product Portfolio
7.7 Genentech Will Retain Market Share
7.8 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug
7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
7.10 Eli Lilly: Market Position is Dependent on Success of Effient
7.11 Sandoz: A Gradually Declining Share of the Market
8. Qualitative Analysis of the Antithrombotic Drug Market, 2014-2024
8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2014
8.1.1 Thrombotic Disease: Management Rather Than Cure
8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
8.2 The Opportunities and Threats Facing the Market 2014-2024
8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
8.2.2 Further Development of Existing Drugs
8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
8.2.4 The Threat of Generic Competition
8.2.5 High Level of Competition is a Threat to New Entrants – What Can Developers Do?
8.2.6 High Risk of Investment in New Drug Development
8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
8.3 The Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2014-2024
8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
8.3.3 Economic Factors
8.3.3.1 Cost Cutting in the EU and the US
8.3.3.2 Free Trade Within the EU Presents Challenges
8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?
9. Research Interviews
9.1 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil
9.1.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
9.1.2 Heparin vs. Novel Oral Anticoagulants
9.1.3 Unmet Needs in Brazil and Worldwide
9.1.4 Trends in the Antithrombotic Drug Market
9.2 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor College of Medicine, Houston, Texas
9.2.1 Warfarin vs. Novel Oral Anticoagulants
9.2.2 The Unmet Needs of the Market
9.2.3 The Antithrombotic R&D Pipeline
9.2.4 Key Market Drivers and Restraints
9.3 Interview with Dr Walter Ageno, Associate Professor of Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Italy
9.3.1 Unmet Needs
9.3.2 Future Focus of Antithrombotic Therapy
9.3.3 The Antithrombotic R&D Pipeline
9.3.4 Key Market Drivers and Restraints
9.3.5 Opportunities in the Market
9.4 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
9.4.1 Unmet Needs
9.4.2 New Findings
9.4.3 Warfarin Replacement
9.4.4 Areas Demanding Attention
9.4.5 Key Market Restraints
10. Conclusions from Our Study
10.1 The World Market for Antithrombotic Drugs 2014-2024
10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
10.2 The Leading National Markets 2014-2024
10.3 Trends in the Industry
10.3.1 The Market Will Recover From Plavix Decline
10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
10.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications



List of Tables
Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2012 and 2013
Table 3.2 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024
Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m) and Market Share (%) Forecasts, 2013-2024
Table 3.5 Antiplatelet Drugs: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.6 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024
Table 3.7 Heparins: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.8 Direct Thrombin Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.9 Direct Factor Xa Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.10 The Warfarin Market: Companies and Year of Introduction
Table 3.11 Vitamin K Antagonists: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.12 Fibrinolytics: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2012 and 2013
Table 4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 4.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Table 4.4 The US Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.5 The EU5 Market for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Table 4.6 The German Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.7 The French Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.8 The UK Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.9 The Italian Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.10 The Spanish Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.11 The Japanese Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.12 The Chinese Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.13 The Brazilian Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.14 The Indian Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.15 The Russian Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.1 The Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2012 and 2013
Table 5.2 The Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 5.3 The Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Table 5.4 Plavix: Key Facts, 2014
Table 5.5 Plavix: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.6 Lovenox: Key Facts, 2014
Table 5.7 Lovenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.8 Pradaxa: Key Facts, 2014
Table 5.9 Pradaxa: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.10 Xarelto: Key Facts, 2014
Table 5.11 Xarelto: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.12 Activase: Key Facts, 2014
Table 5.13 Activase: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.14 Effient: Key Facts, 2014
Table 5.15 Effient: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.16 Aspirin Cardio: Key Facts, 2014
Table 5.17 Aspirin Cardio: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.18 Angiomax: Key Facts, 2014
Table 5.19 Angiomax: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.20 Pletal: Key Facts, 2014
Table 5.21 Pletal: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.22 Aggrenox: Key Facts, 2014
Table 5.23 Aggrenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.24 Sandoz's Enoxaparin Sodium: Key Facts, 2014
Table 5.25 Sandoz's Enoxaparin Sodium: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.26 Fragmin: Key Facts, 2014
Table 5.27 Fragmin: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.28 Arixtra: Key Facts, 2014
Table 5.29 Arixtra: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.30 Brilinta: Key Facts, 2014
Table 5.31 Brilinta: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.32 Eliquis: Key Facts, 2014
Table 5.33 Eliquis: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 6.1 The Antiplatelet Drug R&D Pipeline, 2014
Table 6.2 The Heparins Pipeline, 2014
Table 6.3 The Vitamin K Antagonist Pipeline, 2014
Table 6.4 The Direct Thrombin Inhibitors Pipeline, 2014
Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014
Table 6.6 The Fibrinolytics R&D Pipeline, 2014
Table 6.7 Other Antithrombotic Drugs in the Pipeline, 2014
Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2012 and 2013
Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014
Table 7.3 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014
Table 7.4 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014
Table 7.5 Bayer: Antithrombotic Drug Portfolio, 2014
Table 7.6 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014
Table 7.7 Genentech: Antithrombotic Drug Portfolio, 2014
Table 7.8 The Medicines Company: Antithrombotic Drug Portfolio, 2014
Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014
Table 7.10 Eli Lilly: Antithrombotic Drug Portfolio, 2014
Table 7.11 Sandoz: Antithrombotic Drug Portfolio, 2014
Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2014
Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2014-2024
Table 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market (STEP Analysis), 2014-2024
List of Figures
Figure 2.1 Diagram Depicting the Coagulation Cascade, 2013
Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2012
Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013
Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024
Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2018
Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2024
Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2013-2024
Figure 3.8 Antiplatelet Drugs: Revenue Forecast ($m), 2013-2024
Figure 3.9 The Antiplatelet Drug Market: Drivers and Restraints, 2014-2024
Figure 3.10 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024
Figure 3.11 Heparins: Revenue Forecast ($m), 2013-2024
Figure 3.12 The Heparins Market: Drivers and Restraints, 2014-2024
Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2013-2024
Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2014-2024
Figure 3.15 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2013-2024
Figure 3.16 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2014-2024
Figure 3.17 Vitamin K Antagonists: Revenue Forecast ($m), 2013-2024
Figure 3.18 The Vitamin K Antagonist Market: Drivers and Restraints, 2014-2024
Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2013-2024
Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Antithrombotic Drug Market by Country: Market Shares (%), 2012
Figure 4.2 The Antithrombotic Drug Market by Country: Market Shares (%), 2013
Figure 4.3 The Antithrombotic Drug Market by Country: Market Shares (%), 2018
Figure 4.4 The Antithrombotic Drug Market by Country: Market Shares (%), 2024
Figure 4.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Figure 4.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Figure 4.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 4.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024
Figure 4.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024
Figure 5.1 The Leading Antithrombotic Drugs: Market Shares (%), 2012
Figure 5.2 The Leading Antithrombotic Drugs: Market Shares (%), 2013
Figure 5.3 The Leading Antithrombotic Drugs: Market Shares (%), 2018
Figure 5.4 The Leading Antithrombotic Drugs: Market Shares (%), 2024
Figure 5.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024
Figure 5.6 Plavix: Revenue Forecast ($m), 2013-2024
Figure 5.7 Lovenox: Revenue Forecast ($m), 2013-2024
Figure 5.8 Pradaxa: Revenue Forecast ($m), 2013-2024
Figure 5.9 Xarelto: Revenue Forecast ($m), 2013-2024
Figure 5.10 Activase: Revenue Forecast ($m), 2013-2024
Figure 5.11 Effient: Revenue Forecast ($m), 2013-2024
Figure 5.12 Aspirin Cardio: Revenue ($m) Forecast, 2013-2024
Figure 5.13 Angiomax: Revenue Forecast ($m), 2013-2024
Figure 5.14 Pletal: Revenue Forecast ($m), 2013-2024
Figure 5.15 Aggrenox: Revenue Forecast ($m), 2013-2024
Figure 5.16 Sandoz's Enoxaparin Sodium: Revenue Forecast ($m), 2013-2024
Figure 5.17 Fragmin: Revenue Forecast ($m), 2013-2024
Figure 5.18 Arixtra: Revenue Forecast ($m), 2013-2024
Figure 5.19 Brilinta: Revenue Forecast ($m), 2013-2024
Figure 5.20 Eliquis: Revenue Forecast ($m), 2013-2024
Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014
Figure 7.1 The Top 10 Leading Companies: Market Shares (%), 2012
Figure 7.2 The Top 10 Leading Companies: Market Shares (%), 2013
Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2013-2024
Figure 10.2 The National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2012, 2018 and 2024


【掲載企業】

Abbott Laboratories
Ablynx
Aché
AdvanceCor
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
App Pharmaceuticals
ARCA Biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Barr Laboratories
Bayer
Baylor College of Medicine, Houston, Texas
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Canyon Pharmaceuticals
Committee on Medicinal Products for Human Use (CHMP)
CSL Behring
Daiichi Sankyo
Dexa Medica Group
Diakron Pharmaceuticals
Dr. Reddy's Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fournier Pharma
Gate Pharmaceuticals
Genentech
German Institute for Quality and Efficiency in Health Care (IQWiG)
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hoechst Marion Roussell
Hospira
Hypermarcas
Indonesia University
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
Lee's Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Sandoz
Sanofi
Sun Pharmaceuticals
Takeda
Taro
Teva Pharmaceuticals
The Medicines Company
ThromboGenics
Tianjin Medical
Tufts Medical Center
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
Upjohn AB
US Department of Justice
USL Pharma
Virginia Commonwealth University
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila


【レポートのキーワード】

抗血栓薬、抗血栓剤、血小板凝集阻害薬

★調査レポート[抗血栓薬(Antithrombotic Drug)のグローバル市場(2014-2024)] ( Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 / Visiongain-4052625) 販売に関する免責事項
[抗血栓薬(Antithrombotic Drug)のグローバル市場(2014-2024)] ( Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 / Visiongain-4052625) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆